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Abstract—Adverse drug reaction (ADR) is widely concerned for
public health issue. ADRs are one of most common causes to
withdraw some drugs from market. Prescription event
monitoring (PEM) is an important approach to detect the
adverse drug reactions. The main problem to deal with this
method is how to automatically extract the medical events or
side effects from high-throughput medical data, which are
collected from day to day clinical practice. In this study we
propose an original approach to detect the ADRs using feature
matrix and feature selection. The experiments are carried out on
the drug Pravastatin. Major side effects for the drug are
detected. The detected ADRs are based on computerized
method, further investigation is needed.
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I. INTRODUCTION
Adverse drug reaction (ADR) is widely concerned for
public health issue. ADRs are one of most common causes to
withdraw some drugs from market [1]. Now two major
methods for detecting ADRs are spontaneous reporting
system (SRS) [2,3,4,5], and prescription event monitoring
(PEM) [6,7,8,9,10]. The World Health Organization (WHO)
defines a signal in pharmacovigilance as "any reported
information on a possible causal relationship between an
adverse event and a drug, the relationship being unknown or
incompletely documented previously" [11]. For spontaneous
reporting system, many machine learning methods are used to
detect ADRs, such as Bayesian confidence propagation neural
network (BCPNN) [12,13], decision support method [14],
genetic algorithm [15], knowledge based approach [16,17], etc.
One limitation is the reporting mechanism to submit ADR
reports [14], which has serious underreporting and is not able
to accurately quantify the corresponding risk. Another
limitation is hard to detect ADRs with small number of
occurrences of each drug-event association in the database.
Prescription event monitoring has been developed by the
Drug Safety Research Unit (DSRU) and is the first large-scale
systematic post-marketing surveillance method to use event
monitoring in the UK [8]. The health data are widely and
routinely collected. It is a key step for PEM methods to
automatically detect the ADRs from thousands of medical
events. In paper [18,19], MUTARA and HUNT, which are
based on a domain-driven knowledge representation
Unexpected Temporal Association Rule, are proposed to
signal unexpected and infrequent patterns characteristic of
ADRs, using Queensland Hospital morbidity data, more
commonly referred to as the Queensland Linked Data Set
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(QLDS) [20]. But their methods achieve low accuracies for
detecting ADRs.
In this paper we propose feature selection approach to
detect ADRs from The Health Improvement Network
(THIN) database. First feature matrix, which represents the
medical events for the patients before and after taking drugs,
is created by linking patients' prescriptions and corresponding
medical events together. Then significant features are selected
based on feature selection methods, comparing the feature
matrix before patients take drugs with one after patients take
drugs. Finally the significant ADRs can be detected from
thousands of medical events based on corresponding features.
Experiments are carried out on the drug Pravastatin. Good
performance is achieved.
II.FEATUREMATRIXANDFEATURESELECTION
A. The THIN Database
The Health Improvement Network (THIN) is a
collaboration product between two companies of EPIC and
InPS. EPIC is a research organization, which provides the
electronic database of patient care records from UK and other
countries. There are 'Therapy' and 'Medical' databases in THIN
data. The "Therapy" database contains the details of
prescriptions issued to patients. Information of patients and the
prescription date for the drug can be obtained. The "Medical"
database contains a record of symptoms, diagnoses, and
interventions recorded by the general practice (GP) and/or
primary care team. Each symptom for patients forms a record.
By linking patient identifier, their prescriptions, and their
corresponding medical events (symptoms) together, feature
matrix to characterize the symptoms during the period before or
after patients take drugs is built.
B. The Extraction of Feature Matrix
To detect the ADRs of drugs, first feature matrix is
extracted from THIN database, which describes the medical
events that patients occur before or after taking drugs. Then
feature selection method of Student's t-test is performed to
select the significant features from feature matrix containing
thousands of medical events. Figure 1 shows the process to
detect the ADRs using feature matrix. Feature matrix A
(Figure 2) describes the medical events for each patient
during 60 days before they take drugs. Feature matrix B
reflects the medical events during 60 days after patients take
drugs. In order to reduce the effect of the small events, and
save the computation time and space, we set 100 patients as a
group. Matrix X and Y are feature matrix after patients are
divided into groups.
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D. Feature Selection Based on Student's t-test
Feature extraction and feature selection are widely used in
biomedical data processing [21-27]. In our research we use
Student's t-test [28] feature selection method to detect the
significant ADRs from thousands of medical events. Student's
t-test is a kind of statistical hypothesis test based on a normal
distribution, and is used to measure the difference between
two kinds of samples.
Prescription
date
• A or B
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Figure 1. The process to detect ADRs. Matrix A and B are
feature matrix before patients take drugs or after patients take
drugs. The time period of observation is set to 60 days.
Matrix X and Y are feature matrix after patients are divided
into groups. We set 100 patients as one group.
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Figure 2. Feature matrix. The row of feature matrix represents
the patients, and the column of feature matrix represents the
medical events. The element of events is 1 or 0, which
represents the patient having or not having the corresponding
medical symptom or event.
C. Medical Events and Readcodes
Medical events or symptoms are represented by medical
codes or Readcodes. There are 103387 types of medical
events in "Readcodes" database. The Read Codes used in
general practice (GP), were invented and developed by Dr
James Read in 1982. The NHS (National Health Service) has
expanded the codes to cover all areas of clinical practice. The
code is hierarchical from left to right or from level 1 to level
5. It means that it gives more detailed information from level
1 to level 5. Table 1 shows the medical symptoms based on
Readcodes at level 3 and at level 5. 'Other soft tissue
disorders' is general term using Readcodes at level 3. 'Foot
pain', 'Heel pain', etc., give more details using Readcodes at
level 5.
TABLE I. TABLE I. MEDICAL EVENTS BASED ON READCODES AT
LEVEL 3 ANDLEVEL 5.
Level Readcodes Medical events
Level 3 N24..00 Other soft tissue disorders
Muscle N245.16 Leg pain
pain N245111 Toe pain
Level 5 N245.13 Foot pain
N245700 Shoulder pain
N245.15 Heel pain
E. Other parameters
The variable of ratio R, is defined to evaluate significant
changes of the medical events, using ratio of the patient
number after taking the drug to one before taking the drug.
The variable R2 represents the ratio of patient number after
taking the drug to the number of whole population having
one particular medical symptom.
The ratio variables R, and R2 are defined as follows:
Ri= [N ,/sTB if NB *0;
NA if NB = 0;
R2 = NAI N
where NB and NA represent the numbers of patients before
or after they take drugs for having one particular medical
event respectively. The variable N represents the number of
whole population who take drugs.
III . EXPERIMENTS AND RESULTS
The drug Pravastatin is used to test our proposed method,
using 475 GPs data in THIN database. Student's t-test is
performed to select the significant features from feature
matrix, which represent the medical events having the
significant changes after patients take the drugs.
Drugs.com provides access to healthcare information
tailored for a professional audience, sourced solely from the
most trusted, well-respected and independant agents such as
the Food and Drug Administration (FDA), American Society
of Health-System Pharmacists, Wolters Kluwer Health,
Thomson Micromedex, Cerner Multum and Stedman's. In the
Drugs.com [29], side effects for Pravastatin are listed, such as
severe allergic reactions (rash; hives; itching; difficulty
breathing; tightness in the chest; swelling of the mouth, face,
lips, or tongue); change in the amount of urine produced;
chest pain; dark urine; fever, chills, or persistent sore throat;
flu-like symptoms; muscle pain, tenderness, or weakness (with
or without fever or fatigue); pale stools; red, swollen,
blistered, or peeling skin; severe stomach pain; vision changes;
yellowing of the eyes or skin, etc.
There are seven currently prescribed forms of statin drugs.
They are Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin,
Fluvastatin, Lovastatin, Pitavastatin, muscle pain and
musculoskeletal events [29, 30] are two of the main side
effects of statin drugs.
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In experiments, we use two kinds of feature matrix. One
feature matrix is based on all medical events using Readcodes at
level 1-5 in order to observe the detailed symptoms. Another
one is based on the medical events using Readcodes at level 13,
combining the detailed information of Readcodes at level 4 and
5 into one general term using Readcodes at level 3. 10875
patients from half data of 475GPs are taking Pravastatin. 13438
medical events or symptoms are obtained using Readcodes at
level 1-5, and the feature matrix of 10875x13438 is formed to
describe the detailed information of patients. After grouping
them, 108x13435 feature matrix is obtained. For Readcodes at
level 1-3, 108x2764 feature matrix is obtained.
Table 2 shows the top 20 detected results in ascending
order of p value of Student's t-test, using Readcodes at level 15
and at level 1-3. The detected results are using p values less than
0.05, which represent the significant change after patients take
the drug. Table 3 shows the results in descending order of the
ratio of the number of patients after taking the drug to one
before taking the drug. Our detected results are consistent with
the listed results in [29,30]. Table 4 shows cancer information
related to the patients who take the drug Pravastatin.
IV. CONCLUSIONS
In this study we propose a novel method to successfully
detect the ADRs using feature matrix and feature selection. A
feature matrix, which characterizes the medical events before
patients take drugs or after patients take drugs, is created
from THIN database. The feature selection method of
Student's t-test is used to detect the significant features from
thousands of medical events. The significant ADRs, which
are corresponding to significant features, are detected. The
detected ADRs are based on our proposed method, further
investigation is needed.
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TABLE II. THE TOP POTENTIALADRS FOR PRAVASTATIN BASED ON P VALUEOFSTUDENT'S T-TEST.
Rank Readcodes Medical events NB NA R1 R2
Level
1-5
1 1Z12.00 Chronic kidney disease stage 3 84 532 6.33 5.14
2 C34..00 Gout 85 280 329 2.71
3 1M10.00 Knee pain 102 421 4.13 4.07
4 1969.00 Abdominal pain 81 389 4.80 3.76
5 A53..11 Shingles 16 153 9.56 1.48
6 1D14.00 C/O: a rash 135 497 3.68 4.80
7 M03z000 Cellulitis NOS 37 252 6.81 2.43
8 N245.17 Shoulder pain 130 488 3.75 4.71
9 F4C0.00 Acute conjunctivitis 69 288 4.17 2.78
10 N131.00 Cervicalgia - pain in neck 129 419 325 4.05
11 1C9..00 Sore throat symptom 61 280 4.59 2.71
12 C10F.00 Type 2 diabetes mellitus 183 507 2.77 4.90
13 F46..00 Cataract 33 219 6.64 2.12
14 H06z000 Chest infection NOS 132 688 5.21 6.65
15 N143.00 Sciatica 78 291 3.73 2.81
16 H01..00 Acute sinusitis 53 218 4.11 2.11
17 H060.00 Acute bronchitis 58 329 5.67 3.18
18 16C6.00 Back pain without radiation NOS 107 407 3.80 3.93
19 J16y400 Dyspepsia 122 384 3.15 3.71
20 N245.13 Foot pain 36 205 5.69 1.98
Level
1-3
1 171..00 Cough 473 1799 3.80 16.54
2 H06..00 Acute bronchitis and bronchiolitis 383 1574 4.11 14.47
3 N21..00 Peripheral enthesopathies and allied syndromes 184 685 3.72 6.30
4 1Z1..00 Chronic renal impairment 139 758 5.45 6.97
5 M22..00 Other dermatoses 97 476 4.91 4.38
6 1B8..00 Eye symptoms 125 542 4.34 4.98
7 N24..00 Other soft tissue disorders 750 1933 2.58 17.77
8 H05..00 Other acute upper respiratory infections 179 862 4.82 7.93
9 F4C..00 Disorders of conjunctiva 128 537 420 4.94
10 19F..00 Diarrhoea symptoms 147 633 4.31 5.82
11 1B1..00 General nervous symptoms 307 1052 3.43 9.67
12 N14..00 Other and unspecified back disorders 237 876 3.70 8.06
13 M03..00 Other cellulitis and abscess 79 404 5.11 3.71
14 16C..00 Backache symptom 233 851 3.65 7.83
15 1M1..00 Pain in lower limb 125 536 4.29 4.93
16 N09..00 Other and unspecified joint disorders 320 1058 3.31 9.73
17 K19..00 Other urethral and urinary tract disorders 179 725 4.05 6.67
18 196..00 Type of GIT pain 149 588 3.95 5.41
19 1D1..00 C/O: a general symptom 352 1126 320 10.35
20 ABO..00 Dermatophytosis including tinea or ringworm 87 393 4.52 3.61
Variable NB and NA represent the numbers of patients before or after they take drugs for having one particular medical event. Variable R1represents the ratio of the numbers
of patients after taking drugs to the numbers of patients before taking drugs. Variable R2 represents the ratio of the numbers of patients after taking drugs to the number of the
whole population.
TABLE III. THE POTENTIAL ADRs FOR PRAVASTATIN BASED ON DESCENDING ORDER OF R1 VALUE.
Rank Readcodes Medical events NB NA RI R2
Level
1-5
1 F591.00 Sensorineural hearing loss 1 36 36.00 0.33
2 J574700 Anal pain 1 26 26.00 0.24
3 16J4.00 Swollen knee 0 25 25.00 0.23
4 D010.00 Pernicious anaemia 1 25 25.00 0.23
5 M22z.11 Actinic keratosis 1 25 25.00 0.23
6 A080300 Infectious gastroenteritis 1 24 24.00 0.22
7 B49..00 Malignant neoplasm of urinary bladder 1 23 23.00 0.21
8 1NO3.00 C/O: dry skin 1 22 22.00 0.20
9 F420600 Non proliferative diabetic retinopathy 0 21 21.00 0.19
10 F42y900 Macular oedema 1 20 20.00 0.18
11 K190311 Recurrent UTI 1 19 19.00 0.17
12 173C.12 SOBOE 0 19 19.00 0.17
13 SKz..00 Injury NOS 1 18 18.00 0.17
14 1CA2.11 Voice hoarseness 3 53 17.67 0.49
15 J578.00 Colonic polyp 2 35 17.50 0.32
16 SE3..11 Arm bruise 1 17 17.00 0.16
17 16J7.00 Swollen foot 0 17 17.00 0.16
18 1B16.11 Agitated - symptom 1 17 17.00 0.16
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19 S64..13 Head injury 1 17 17.00 0.16
20 G86..11 Lymphoedema 1 16 16.00 0.15
Level
1-3
1 161..00 Appetite symptom 1 34 34.00 0.31
2 SE3..00 Contusion, upper limb 1 28 28.00 0.26
3 B49..00 Malignant neoplasm of urinary bladder 1 27 27.00 0.25
4 F4B..00 Comeal opacity and other disorders of cornea 1 21 21.00 0.19
5 1C7..00 Snoring symptoms 1 18 18.00 0.17
6 1BD..00 Harmful thoughts 1 18 18.00 0.17
7 SKz..00 Injury NOS 1 18 18.00 0.17
8 D31..00 Purpura and other haemorrhagic conditions 2 33 16.50 0.30
9 M25..00 Disorders of sweat glands 2 33 16.50 0.30
10 HOz..00 Acute respiratory infection NOS 1 16 16.00 0.15
11 BB1..00 [M]Epithelial neoplasms NOS 1 15 15.00 0.14
12 F41..00 Retinal detachments and defects 1 15 15.00 0.14
13 G41..00 Chronic puhnonary heart disease 1 15 15.00 0.14
14 K08..00 Impaired renal function disorder 1 15 15.00 0.14
15 B7J..00 Haemangiomas and lymphangiomas of any site 1 15 15.00 0.14
16 1NO..00 Skin symptoms 2 29 14.50 0.27
17 SA1..00 Open wound of knee, leg and ankle 0 14 14.00 0.13
18 S93..00 Open wound of fmger(s) or thumb 0 14 14.00 0.13
19 S24..00 Fracture of carpal bone 1 14 14.00 0.13
20 SD7..00 Superficial injury of foot and toe(s) 1 14 14.00 0.13
21 1A3..00 Micturition stream 3 39 13.00 0.36
22 B83..00 Carcinoma in situ of breast and genitourinary system 0 13 13.00 0.12
23 F17..00 Autonomic nervous system disorders 0 13 13.00 0.12
24 K11..00 Hydronephrosis 0 13 13.00 0.12
25 F33..00 Nerve root and plexus disorders 1 13 13.00 0.12
26 E26..00 Physiological malfunction arising from mental factors 1 13 13.00 0.12
27 A38..00 Septicaemia 2 24 12.00 0.22
28 K13..00 Other kidney and ureter disorders 0 12 12.00 0.11
29 F40..00 Disorders of the globe 0 11 11.00 0.10
30 F12..00 Parkinson's disease 3 32 10.67 0.29
TABLEIV. THEPOTENTIALADRsRELATEDTOCANCERFORPRAVASTATINBASEDONPVALUEOFSTUDENTST-TEST.
Rank Readcodes Medical events NB NA R1 R2
Cancer
( level 1-
5)
1 B33..11 Basal cell carcinoma 29 126 4.34 1.16
2 B46..00 Malignant neoplasm of prostate 8 47 5.88 0.43
3 B49..00 Malignant neoplasm of urinary bladder 1 23 23.00 0.21
4 BB2A.00 [M]Squamous cell carcinoma NOS 2 29 14.50 0.27
5 B34..00 Malignant neoplasm of female breast 7 30 4.29 0.28
6 BB2..12 [M]Squamous cell neoplasms 2 17 8.50 0.16
7 B32..00 Malignant melanoma of skin 0 9 9.00 0.08
8 B13..00 Malignant neoplasm of colon 2 15 7.50 0.14
9 B22z.00 Malignant neoplasm of bronchus or lung NOS 4 16 4.00 0.15
10 B10..00 Malignant neoplasm of oesophagus 1 9 9.00 0.08
11 BB5..11 [M]Adenocarcinomas 4 15 3.75 0.14
12 B22..00 Malignant neoplasm of trachea, bronchus and lung 0 6 6.00 0.06
13 B585.00 Secondary malignant neoplasm of bone and bone marrow 0 6 6.00 0.06
14 B141.00 Malignant neoplasm of rectum 0 6 6.00 0.06
15 B834.00 Carcinoma in situ of prostate 0 5 5.00 0.05
16 BB12.00 [M]Carcinoma NOS 0 5 5.00 0.05
17 BB31.00 [M]Basal cell carcinoma NOS 1 7 7.00 0.06
18 B49z.00 Malignant neoplasm of urinary bladder NOS 0 6 6.00 0.06
19 B133.00 Malignant neoplasm of sigmoid colon 0 4 4.00 0.04
20 BB5M.00 [M]Tubular adenomas and adenocarcinomas 0 4 4.00 0.04
21 B590.11 Carcinomatosis 0 4 4.00 0.04
22 BB13.00 [M]Carcinoma, metastatic, NOS 1 6 6.00 0.06
23 BBEF.11 [M]Lentigo maligna 0 3 3.00 0.03
24 B577.00 Secondary malignant neoplasm of liver 0 3 3.00 0.03
25 H51y700 Malignant pleural effusion 0 3 3.00 0.03
26 B222.00 Malignant neoplasm of upper lobe, bronchus or lung 0 3 3.00 0.03
27 BB5y000 [M]Basal cell adenocarcinoma 0 3 3.00 0.03
28 1J0..00 Suspected malignancy 0 3 3.00 0.03
29 B134.00 Malignant neoplasm of caecum 0 3 3.00 0.03
30 BB2B.00 [M]Squamous cell carcinoma, metastatic NOS 0 3 3.00 0.03
